New eczema drug shows promise in early safety trial

NCT ID NCT06248814

Completed Symptom relief Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 02, 2026 · Updated 18 times

Summary

This early-stage study tested a new drug called BMS-986326 in 64 adults with moderate-to-severe atopic dermatitis (eczema). The main goal was to check the drug's safety and how the body processes it. Participants received a single dose of the drug or a placebo, and researchers monitored side effects and changes in immune cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution - 0001

Rzeszów, Podkarpackie Voivodeship, 35-055, Poland
Local Institution - 0002

Córdoba, X, 14004, Spain
Local Institution - 0004

Prague, PR, 100 00, Czechia
Local Institution - 0005

Chemnitz, Saxony, 09117, Germany
Local Institution - 0006

Clermont-Ferrand, 63003, France
Local Institution - 0008

Pierre-Bénite, 69495, France
Local Institution - 0009

Pardubice, 530 02, Czechia
Local Institution - 0010

Nice, 06200, France
Local Institution - 0011

Berlin, State of Berlin, 10117, Germany
Local Institution - 0012

Lübeck, Schleswig-Holstein, 23562, Germany
Local Institution - 0013

Las Palmas de Gran Canaria, GC, 35010, Spain
Local Institution - 0015

Krakow, Lesser Poland Voivodeship, 30-149, Poland
Local Institution - 0016

Katowice, Silesian Voivodeship, 40-081, Poland

Conditions

Explore the condition pages connected to this study.

DERMATITIS, ATOPIC